Lexeo Therapeutics, Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | +219.6% | -60.5% | -100.0% | – | – | |
| – | – | +8,441.6% | +61.0% | +8.6% | +3.8% | |
| – | +219.6% | -60.5% | -381.8% | – | – | |
| – | +944.8% | +9.0% | +8.1% | +39.5% | -13.9% | |
| – | +810.9% | +67.3% | +28.2% | +105.9% | +43.5% | |
| – | +924.1% | +17.0% | +12.0% | +54.4% | +3.3% | |
| – | – | – | – | – | – | |
| – | -100.0% | – | +125.3% | -44.4% | +80.7% | |
| – | – | – | – | – | – | |
| – | -100.1% | – | -100.0% | – | – | |
| – | – | – | – | – | – | |
| – | – | – | – | – | – |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.